Case Study References

Bousquet J, Schünemann HJ, Hellings PW, Arnavielhe S, Bachert C, Bedbrook A et al. MACVIA clinical decision algorithm in allergic rhinitis in adolescents and adults. J Allergy Clin Immunol. 2016;138(2):367–74.

Dymista Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/medicine/27579/SPC/Dymista+Nasal+Spray/

Lohia S, Schlosser J, Soler ZM. Impact of intranasal corticosteroids on asthma outcomes in allergic rhinitis: a meta-analysis. Allergy. 2013;68(5):569–79.

Marple BF, Fornadley JA, Patel AA, Fineman SM, Fromer L, Krouse JH et al. Keys to successful management of patients with allergic rhinitis: Focus on patient confidence, compliance and satisfaction. Otolaryngol Head Neck Surg. 2007;136(6Suppl):S107–24.

Meltzer EO, LaForce C, Ratner P, Price D, Ginsberg D, Carr W. MP29-02 (a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis: A randomized, double-blind, placebo-controlled trial of efficacy and safety. Allergy Asthma Proc. 2012;33:324–32.

Meltzer E, Ratner P, Bachert C, Carr W, Berger W, Canonica GW et al. Clinically relevant effect of a new intranasal therapy (MP29-02) in allergic rhinitis assessed by responder analysis. Int Arch Allergy Immunol. 2013;161:369–77.

Price D, Kemp L, Sims E, von Ziegenweidt J, Navaratnam P, Lee AJ et al. Observational study comparing intranasal mometasone furoate with oral antihistamines for rhinitis and asthma. Prim Care Respir J. 2010;19(3):266–73.


 

Login/ Register Maximise Minimise

Alternatively login via